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IMPORTANCE Although nonparticipation in cardiac rehabilitation is known to increase
cardiovascular mortality and hospital readmissions, more than half of patients with coronary
artery disease in Europe are not participating in cardiac rehabilitation.
OBJECTIVE To assess whether a 6-month guided mobile cardiac rehabilitation (MCR) program
is an effective therapy for elderly patients who decline participation in cardiac rehabilitation.
DESIGN, SETTING, AND PARTICIPANTS Patients were enrolled in this parallel multicenter
randomized clinical trial from November 11, 2015, to January 3, 2018, and follow-up was
completed on January 17, 2019, in a secondary care system with 6 cardiac institutions across 5
European countries. Researchers assessing primary outcome were masked for group
assignment. A total of 4236 patients were identified with a recent diagnosis of acute
coronary syndrome, coronary revascularization, or surgical or percutaneous treatment for
valvular disease, or documented coronary artery disease, of whom 996 declined to start
cardiac rehabilitation. Subsequently, 179 patients who met the inclusion and exclusion criteria
consented to participate in the European Study on Effectiveness and Sustainability of Current
Cardiac Rehabilitation Programmes in the Elderly trial. Data were analyzed from January 21 to
October 11, 2019.
INTERVENTIONS Six months of home-based cardiac rehabilitation with telemonitoring and
coaching based on motivational interviewing was used to stimulate patients to reach exercise
goals. Control patients did not receive any form of cardiac rehabilitation throughout the study
period.
MAIN OUTCOMES AND MEASURES The primary outcome parameter was peak oxygen uptake
(VO2peak) after 6 months.
RESULTS Among 179 patients randomized (145 male [81%]; median age, 72 [range, 65-87]
years), 159 (89%) were eligible for primary end point analysis. Follow-up at 1 year was
completed for 151 patients (84%). Peak oxygen uptake improved in the MCR group (n = 89)
at 6 and 12 months (1.6 [95% CI, 0.9-2.4] mL/kg−1/min−1 and 1.2 [95% CI, 0.4-2.0]
mL/kg−1/min−1, respectively), whereas there was no improvement in the control group
(n = 90) (+0.2 [95% CI, −0.4 to 0.8] mL/kg−1/min−1 and +0.1 [95% CI, −0.5 to 0.7]
mL/kg−1/min−1, respectively). Changes in VO2peak were greater in the MCR vs control groups
at 6 months (+1.2 [95% CI, 0.2 to 2.1] mL/kg−1/min−1) and 12 months (+0.9 [95% CI, 0.05 to
1.8] mL/kg−1/min−1). The incidence of adverse events was low and did not differ between the
MCR and control groups.
CONCLUSIONS AND RELEVANCE These results suggest that a 6-month home-based MCR
program for patients 65 years or older with coronary artery disease or a valvular intervention
was safe and beneficial in improving VO2peak when compared with no cardiac rehabilitation.
TRIAL REGISTRATION trialregister.nl Identifier: NL5168
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A pproximately 50% of patients with coronary artery dis-ease are not referred to participate in cardiacrehabilitation.1 This statistic is even worse for elderly
patients, despite their higher prevalence of comorbidities and
a less physically active lifestyle.2 Transportation difficulties are
a key reason for nonparticipation and further contribute to the
lower cardiac rehabilitation participation rates of older
patients.3 Home-based mobile cardiac rehabilitation (MCR) pro-
grams have been suggested as an alternative for the elderly pa-
tient unable or unwilling to participate in center-based car-
diac rehabilitation.4
The aim of the present study was to assess whether MCR
is an effective therapy for patients 65 years or older who de-
cline participation in a conventional cardiac rehabilitation pro-
gram. We hypothesized that MCR would lead to (1) better physi-
cal fitness at 6-month follow-up, (2) a sustained effect at 12-
month follow-up, (3) an increase in habitual physical activity,
(4) improved cardiovascular risk factors, and (5) lower inci-
dence of adverse events.
Methods
Details of the study methods of the European Study on Effec-
tiveness and Sustainability of Current Cardiac Rehabilitation
Programmes in the Elderly (ER-CaRE) randomized clinical trial
(RCT) have been published previously5; a copy of the trial pro-
tocol is available in Supplement 1. Further details are given in
the eMethods in Supplement 2. In short, this multicenter RCT
was conducted in accordance with the Declaration of Helsinki.6
Six cardiac institutions across 5 European countries partici-
pated. The study protocol was approved by all local ethics com-
mittees, and informed written consent was obtained from all
participants. This study followed Consolidated Standards of
Reporting Trials (CONSORT) reporting guideline.
Patients 65 years or older with a recent diagnosis (<3
months) of acute coronary syndrome, coronary revascular-
ization, surgical or percutaneous treatment for valvular dis-
ease, or documented coronary artery disease defined by stan-
dard noninvasive or invasive methods and who declined
participation in center-based cardiac rehabilitation were eli-
gible for inclusion. Patients were recruited by a research as-
sistant from the participating centers by screening all consecu-
tive patients admitted to the participating centers.
Randomization was performed in fixed blocks of 4, stratified
by center, with a 1:1 ratio to the intervention group (MCR) or a
control group without cardiac rehabilitation using a central-
ized computerized allocation system. Researchers assessing
primary outcomes were blinded for group assignment.
Figure 1. Flowchart (CONSORT) of All Eligible Patients Referred
for Cardiac Rehabilitation in Centers Screened for the European Study
on Effectiveness and Sustainability of Current Cardiac Rehabilitation
Programmes in the Elderly (EU-CaRE)
4236 All eligible patients referred for cardiac rehabilitation
from November 2015 and January 2018 
996 Candidate EU-CaRE RCT (refused participation in CR) (24%) 
90 Randomized to control group 89 Randomized to MCR
90 CPET at start
89 Measured VO2
1 Estimated on 6MWT
80 CPET at T1
79 Measured VO2
1 Estimated on 6MWT
79 CPET at T1
77 Measured VO2
2 Estimated on Watt
78 CPET at T2
77 Measured VO2
1 Estimated on 6MWT
73 CPET at T2
71 Measured VO2
2 Estimated on Watt
88 CPET at start
86 Measured VO2
2 Estimated on Watt
179 Randomized
3 Withdrawal informed
consent EU-CaRE
59 Site (Rome) stopped EU-CaRE
371 Declined participation EU-CaRE
609 Sites not participating in
EU-CaRE RCT
565 Exclusion based on exclusion
criteria
1633 Participated EU-CaRE
observational study
505 Refused participation in
EU-CaRE RCT
312 Exclusion based on exclusion
criteria
1 Withdrawal IC
9 Failed to complete
the study
1 Death
10 Failed to complete
the study
2 Failed to complete
the study
6 Failed to complete
the study
A total of 996 patients (24%) declined participation in cardiac rehabilitation, of
whom 312 were excluded from the EU-CaRE randomized clinical trial. Of the
remaining 684 patients, a total of 179 were willing to participate (26%). CPET
indicates cardiopulmonary exercise test; MCR, mobile cardiac rehabilitation;
VO2, oxygen uptake; and 6MWT 6-minute walking test.
Key Points
Question Is home-based cardiac rehabilitation an effective
therapy for elderly patients who decline conventional cardiac
rehabilitation?
Findings In this international, multicenter, randomized clinical
trial including 179 patients, 6 months of home-based mobile
cardiac rehabilitation was associated with a greater increase in
physical fitness compared with no cardiac rehabilitation. These
beneficial adaptations were sustainable at 1-year follow-up,
whereas the incidence of adverse events was low and similar
between the intervention and control groups.
Meaning These findings suggest that home-based mobile cardiac
rehabilitation for elderly patients is safe and effective in changing
physical fitness for patients that are not able or willing to
participate in conventional cardiac rehabilitation.
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Patients in the MCR group were offered a 6-month home-
based cardiac rehabilitation program in which they were
equipped with a smartphone and heart rate belt. Patients were
instructed to exercise at moderate intensity for at least 30 min-
utes per day, 5 days per week.7 Motivational interviewing was
applied by telephone: weekly in the first month, every other
week in the second month, and monthly until completion of
the MCR program at 6 months (eFigure 1 in Supplement 2). Af-
ter 6 months, the home-based cardiac rehabilitation program
was finished and equipment was handed in. Patients in the con-
trol group did not receive any form of cardiac rehabilitation but
received locally defined standard of care.
The primary end point was the difference in change in
physical fitness from baseline to 6-month follow-up between
MCR and controls. Fitness was defined as the highest 30-
second moving mean peak of oxygen uptake (VO2peak). Self-
reported physical activity was assessed using the following 2
questions: “How many days per week do you perform mod-
erate to vigorous PA [physical activity]?” and “How many min-
utes per day do you perform moderate to vigorous PA?” The
definition of self-reported habitual physical activity was con-
sidered the total number of days per week in which a mini-
mum of 30 minutes of self-reported moderate to vigorous
physical activity was registered. Standardized clinical chemi-
cal blood tests were performed to determine levels of total cho-
lesterol, low-density and high-density lipoprotein choles-
terol, and hemoglobin A1c (HbA1c) in local laboratories. Adverse
events were registered and collected by monthly telephone
calls with participants in both groups and evaluation of pa-
tients’ electronic medical files. A Clinical Event Committee re-
viewed and adjudicated all clinical end point events.
Data were analyzed from January 21 to October 11, 2019.
All parameters were analyzed according to the initial random-
ization. Analyses were performed using SAS, version 9.4 (SAS
Institute, Inc). The primary outcome was assessed by a linear
mixed model with change in VO2peak (6 months difference
from baseline) as response, the intervention (MCR vs control)
as a fixed effect, the effect of center as a random effect, and
adjustment for baseline value of VO2peak. Two-sided P < .05
was considered statistically significant.
Results
From November 11, 2015, to January 3, 2018, a total of 179 of 684
eligiblepatients(26%)whodeclinedparticipationincenter-based
cardiac rehabilitation were included in the study. A CONSORT
flowchart of the trial is presented in Figure 1. The primary reason
for nonparticipation was a perceived lack of usefulness (eFigure 2
in Supplement 2). The trial (including follow-up) ended January
17, 2019, owing to reaching the end date set by the funder. The
median age of participants was 72 (range, 65-87) years, with 20
patients (11%) older than 80 years (eTable 1 in Supplement 2).
Thirty-four patients were female (19%) and 145 were male (81%).
No differences were found in patient characteristics, index event
for cardiac rehabilitation, medication use, and baseline VO2peak.
Patients in the MCR group were more often diagnosed with hy-
pertension (73 of 89 [82%] vs 60 of 90 [67%]).
Peak oxygen uptake increased after 6 months (1.6 [95% CI,
0.9 to 2.4] mL/kg−1/min−1; relative increase of 8.5%) and 12
months (1.2 [95% CI, 0.4 to 2.0] mL/kg−1/min−1; relative in-
crease of 6.3%) for patients in the MCR group, whereas no
changes were observed for the control group (6 months, +0.2
[95% CI, −0.4 to 0.8] mL/kg−1/min−1; 12 months, +0.1 [95% CI,
−0.5 to 0.7] mL/kg−1/min−1) (eTable 2 in Supplement 2). Change
in VO2peak was higher in the MCR compared with the control
group at 6 months (+1.2 [95% CI, 0.2 to 2.1] mL/kg−1/min−1) and
12 months (+0.9 [95% CI, 0.05 to 1.8] mL/kg−1/min−1) (Figure 2).
Likewise, change in the amount of self-reported habitual physi-
cal activity was greater in the MCR compared with the con-
trol group (mean absolute difference, 0.7 [95% CI, 0.1-1.3])
(Figure 3). Diastolic blood pressure remained stable at 6 months
in the MCR group (mean [SD] change from baseline, 78 [11] to
76 [12] mm Hg) and increased in the control group (mean [SD]
Figure 2. Primary Outcome of Change in Peak Oxygen Uptake (VO2peak) at 6 and 12 Months of Follow-up
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Change in VO2peak from baseline to 6 and 12 months follow-up is significantly greater in the mobile cardiac rehabilitation (MCR) intervention group compared with
the control group. Data are presented as mean (95% CI). The difference between groups with 95% CI is displayed at the top.
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change from baseline, 76 [12] to 78 [11]). In contrast, HbA1c level
increased in the control group at 12 months (mean [SD] change
from baseline, 40.4 [5.7] to 42.0 [8.2] mmol/mol), whereas it
remained stable in the MCR group (mean [SD] change from
baseline, 42.6 [9.4] to 42.0 [8.1] mmol/mol) (eTable 2 in Supple-
ment 2). Changes in other cardiovascular biomarkers did not
differ between the MCR and control groups, and no differ-
ences were found in quality of life. The incidence of serious
adverse events did not differ between the MCR and control
groups (12 of 89 [13%] vs 10 of 90 [11%]; P = .66) (eTable 3 in
Supplement 2). Most patients were hospitalized for acute (6
of 19 [3%]) or chronic (8 of 19 [42%]) coronary syndrome.
Discussion
A 6-month home-based cardiac rehabilitation program for el-
derly patients who declined participation in conventional car-
diac rehabilitation was beneficial in terms of change in physi-
cal fitness. These adaptations proved to be sustainable at 1-year
follow-up. Moreover, MCR proved to be safe, because the in-
cidence of adverse events was low and similar to rates ob-
served in the control group. Patients in the MCR group dem-
onstrated a greater increase in self-reported physical activity,
whereas control patients had an increase in HbA1c level. These
observations indicate that MCR may be a valuable and safe tool
for older patients with cardiac disease who decline hospital-
based cardiac rehabilitation programs.
We found relative increases in physical fitness of 8.5% and
6.3% after 26 and 52 weeks, respectively. The magnitude of these
improvements is beyond the coefficient of variation for assess-
ment of VO2peak (5.9%) and thus can be classified as genuine.8,9
Comparable populations showed a mean increase in exercise ca-
pacity of 16% (absolute, 2.52 [95% CI, 2.32-2.72] mL/kg−1/min−1)10
and 19% (absolute, from 19.4 [5] mL/kg−1/min−1 to 23.9 [6.0]
mL/kg−1/min−1)11 12 months after completion of a center-based
cardiac rehabilitation program, whereas the present study found
an increase of 6.3% (absolute, 1.2 [95% CI, 0.4-2.0] mL/kg−1/
min−1). Potential explanations for the relatively smaller improve-
ment in fitness in MCR may relate to differences in intensity of
the training program and motivation of the patient. Center-
based cardiac rehabilitation may lower anxiety for high-
intensity training, allowing greater increases in VO2peak.12 In ad-
dition, patients willing to participate in conventional cardiac
rehabilitation might also be more motivated to reach exercise tar-
gets, leading to greater fitness improvements.13
Not only physical fitness but also secondary outcome
parameters support the positive findings of MCR. Differences
in secondary outcome parameters all favored MCR and may
be associated with a higher increase in self-reported physical
activity in MCR when compared with a control condition.14
Only 26% of eligible patients who declined center-based
cardiac rehabilitation participated in the present study, which
calls into question the clinical relevance and feasibility of MCR
as a secondary prevention strategy. However, the potential of
MCR may be higher because the EU-CaRE RCT was per-
formed in countries with a relative high availability of cardiac
rehabilitation programs and centers with a high participation
rate.15 In regions with a lower availability of cardiac rehabili-
tation programs and a lower uptake of cardiac rehabilitation,
more patients may benefit from MCR. Mobile cardiac rehabili-
tation can be a safe option for elderly patients who decline par-
ticipating in conventional cardiac rehabilitation, because no
differences were seen in adverse effects across both groups,
and incidence of hospitalization in this vulnerable aged popu-
lation was low.16
Figure 3. Standardized Mean Differences at 6- and 12-Month Follow-up
in Secondary Outcome Parameters
–1.0 0.5 1.00
Standardized mean difference (95% CI) 
–0.5
Parameter
ΔMVPA
Standardized
mean difference 
(95% CI)
0-12 mo 0.7 (0.1 to 1.3)a
ΔGAD-7
0-6 mo
0.1 (–0.8 to 1.0) 0-12 mo
–0.6 (–1.7 to 0.5)
ΔMCS
0-6 mo
0.6 (–1.8 to 3.0)0-12 mo
1.1 (–1.3 to 3.6)
ΔPCS
0-6 mo
1.4 (–0.5 to 3.3)0-12 mo
1.7 (–0.1 to 3.5)
ΔPHQ-9
0-6 mo
–0.2 (–0.9 to 0.9)0-12 mo
–1.0 (–2.1 to 0.2)
ΔDBP, mm Hg
0-6 mo
–0.2 (–3.5 to 3.1)0-12 mo
–3.6 (–6.5 to –0.6)a
ΔSBP, mm Hg
0-6 mo
1.6 (-3.0 to 6.1)0-12 mo
–1.6 (–6.7 to 3.6)
ΔBMI
0-6 mo
–0.6 (–1.5 to 0.3)0-12 mo
 0.1 (-0.8 to 1.0)
ΔHbA1c level, mmol/mol-1
0-6 mo
–2.2 (–4.1 to –0.4)a0-12 mo
–0.7 (–2.2 to 0.7)
ΔHDL level, mmol/L-1
0-6 mo
–0.0 (–0.1 to 0.1)0-12 mo
 0.0 (0.0 to 0.1)
ΔLDL level, mmol/L-1
0-6 mo
 0.2 (–0.1 to 0.4)0-12 mo
 0.0 (–0.2 to 0.2)
ΔCholesterol level, mmol/L-1
0-6 mo
0.0 (–0.2 to 0.4)0-12 mo
0.0 (–0.2 to 0.3)
Compared with the control group, physical activity in days per week with more
than 30 minutes of self-reported moderate to vigorous activity (MVPA) was
significantly higher in the mobile cardiac rehabilitation (MCR) group;
hemoglobin A1c (HbA1c) level after 12 months increased more in the control
group; and diastolic blood pressure (DBP) at 6 months was lower in the MCR
group. BMI indicates body mass index; GAD-7, General Anxiety Disorder
Questionnaire; HDL, high-density lipoprotein cholesterol; LDL, low-density
lipoprotein cholesterol; MCS, mental component score of the 36-Item Short
Form, version 2, survey (SF36v2); PCS, physical component score of the
SF36v2; PHQ-9, Patient Health Questionnaire; and SBP, systolic blood pressure.
a P < .05.
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Strengths and Limitations
The primary strength of the EU-CaRE RCT is that we were able
to include a patient group not willing to participate in conven-
tional center-based cardiac rehabilitation and thereby ad-
dressed an underrepresented group in traditional studies on car-
diac rehabilitation. Moreover, by including different countries
and different cultures, our results are more generalizable to the
rest of the world. One limitation of the study is that we used MCR
as an alternative for exercise-based cardiac rehabilitation and not
for comprehensive cardiac rehabilitation, because we did not in-
clude all core components of cardiac rehabilitation in MCR. Of
note, the EU-CaRE RCT was not powered to detect a difference
in hard outcomes or more rare adverse events.
Conclusions
In this RCT, a home-based MCR program of 6 months for el-
derly patients who decline participation in conventional car-
diac rehabilitation was superior in changing physical fitness
at 6- and 12-month follow-up when compared with usual care
with no cardiac rehabilitation. Furthermore, MCR could be a
safe alternative to improve fitness and increase physical ac-
tivity in older patients. Future studies are warranted to ex-
plore the long-term clinical benefits of MCR in this patient
group, including longevity, attenuated disease progression, and
a reduced risk for adverse cardiovascular events.
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